Open Orphan announced the signing of a contract with Carna Bioscience for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next twelve months. Carna is a Japanese company specialising in kinase biology, developing innovative treatments against cancer and immune disorders. This contract sees Venn Life Sciences provided Carna with a range of expertise from Chemistry Manufacturing and Controls to Clinical Trial Management as well as biometry, legal and regulatory support. This new contract builds upon several years of existing work between Venn and Carna during which both parties closely collaborated on drug development planning and pre-clinical activities services contracts. The contract is further evidence of Open Orphan's strategy to secure long-term partnership contracts which deliver recurring revenues for the business by working in close collaboration with high quality customers.